55
Friocruz signed a preliminary document with the pharmaceutical company responsible for manufacturing Lenacapavir – a biannual HIV prevention injection.
The objective is to evaluate the possible transfer of technology for manufacturing the medicine in Brazil. In practice, this could reduce production costs and make the formula cheaper in the country.
The drug was approved by Anvisa at the beginning of the month and is indicated for “adults and adolescents over 12 years old weighing at least 35 kg who are at risk of acquiring HIV”. Individuals must test negative for the disease before use.
